BiotechTube

Edoxaban + Apixaban + Rivaroxaban

Pre-clinicalCompleted
0 watching 0 views this week💤 Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Atrial Fibrillation

Conditions

Atrial Fibrillation

Trial Timeline

Feb 15, 2019 → Jul 9, 2021

NCT ID
NCT05262322

About Edoxaban + Apixaban + Rivaroxaban

Edoxaban + Apixaban + Rivaroxaban is a pre-clinical stage product being developed by Daiichi Sankyo for Atrial Fibrillation. The current trial status is completed. This product is registered under clinical trial identifier NCT05262322. Target conditions include Atrial Fibrillation.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT05262322Pre-clinicalCompleted

Competing Products

20 competing products in Atrial Fibrillation

See all competitors
ProductCompanyStageHype Score
EdoxabanDaiichi SankyoPre-clinical
23
Edoxaban + Clopidogrel + Prasugrel + Ticagrelor + Vitamin K antagonistDaiichi SankyoPhase 3
77
OAC aloneDaiichi SankyoApproved
85
Edoxaban + ASADaiichi SankyoPhase 3
77
DU-176b tablets + DU-176b tablets + Warfarin tabletsDaiichi SankyoPhase 2
52
Edoxaban + VKA-Based Regimen + VKA-Based Regimen + VKA-Based Regimen + VKA-Based RegimenDaiichi SankyoPhase 3
77
Edoxaban (DU-176b) + Edoxaban (DU-176b) + Edoxaban (DU-176b) + Edoxaban (DU-176b) + warfarinDaiichi SankyoPhase 2
52
EdoxabanDaiichi SankyoPre-clinical
23
EdoxabanDaiichi SankyoApproved
85
Edoxaban + Warfarin + EnoxaparinDaiichi SankyoPhase 3
77
EdoxabanDaiichi SankyoPre-clinical
23
EdoxabanDaiichi SankyoPre-clinical
23
DU-176b 15mg + DU-176b 30mg + DU-176b 60mgDaiichi SankyoPhase 3
77
dabigatran, rivaroxaban, apixaban or edoxabanDaiichi SankyoPre-clinical
23
EdoxabanDaiichi SankyoPre-clinical
23
DU-176b tablets + Warfarin potassium tabletsDaiichi SankyoPhase 2
52
Edoxaban-based Regimen + VKA-based RegimenDaiichi SankyoPhase 3
77
EdoxabanDaiichi SankyoPre-clinical
23
Edoxaban + Aspirin and Clopidogrel + Aspirin and WarfarinDaiichi SankyoApproved
85
EdoxabanDaiichi SankyoPre-clinical
23

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved
85
OAC aloneApproved
85
olmesartan medoxomil + Placebo + losartan potassiumApproved
85
Prasugrel + ClopidogrelApproved
85
Diet+pravastatinApproved
85